Compare AstraZeneca plc (AZN) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Tapestry, Inc. — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Tapestry, Inc. trades at $154.98 (market cap $32.44B). The key difference: AstraZeneca plc is far larger — about 7.6× Tapestry, Inc.'s market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | TPR | |
|---|---|---|
Market Cap | $248.14B | $32.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $164.78 |
52-Week Low | $147.06 | $95.69 |
Enterprise Value | $275.41B | $35.29B |
Dividend Yield | 2.01% | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
TPR trades at $154.39, down 6.31% over 24 hours, with a bullish technical outlook supported by moving averages and strong analyst consensus. Recent earnings beats and a 75.61% buy rating highlight positive momentum. The company maintains robust gross margins of 76.18% and ROE of 55.74%, though elevated P/E of 48.95 signals premium valuation. Upcoming Q4 2026 earnings on August 13, 2026, and a $0.40 dividend payment on June 22, 2026, are key near-term catalysts.
Outlook remains favorable with a consensus price target of $190.33, implying 23% upside, driven by earnings growth and AI integration initiatives. Risks include high debt levels, competitive pressures, and sensitivity to consumer spending. Investors should weigh strong profitability against valuation concerns ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
